DK3325482T3 - Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater - Google Patents
Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater Download PDFInfo
- Publication number
- DK3325482T3 DK3325482T3 DK16745598.9T DK16745598T DK3325482T3 DK 3325482 T3 DK3325482 T3 DK 3325482T3 DK 16745598 T DK16745598 T DK 16745598T DK 3325482 T3 DK3325482 T3 DK 3325482T3
- Authority
- DK
- Denmark
- Prior art keywords
- cytotoxic
- preparation
- methods
- benzodiazepin
- derivatives
- Prior art date
Links
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 0 CC(C)(*)CN(CCOCCOCCOC)c1cc(CO)cc(CO)c1 Chemical compound CC(C)(*)CN(CCOCCOCCOC)c1cc(CO)cc(CO)c1 0.000 description 19
- ROVBYDCETXMZLN-UHFFFAOYSA-N COc(c(O)c1)cc2c1N=CC(Cc1c3cccc1)N3C2=O Chemical compound COc(c(O)c1)cc2c1N=CC(Cc1c3cccc1)N3C2=O ROVBYDCETXMZLN-UHFFFAOYSA-N 0.000 description 2
- ROVBYDCETXMZLN-NSHDSACASA-N COc(c(O)c1)cc2c1N=C[C@H](Cc1c3cccc1)N3C2=O Chemical compound COc(c(O)c1)cc2c1N=C[C@H](Cc1c3cccc1)N3C2=O ROVBYDCETXMZLN-NSHDSACASA-N 0.000 description 2
- WHOMMAJWTHZVJY-WRXSAAJRSA-N CC([C@H](C1)N2c3c1cccc3)Nc(cc(c(OC)c1)O)c1C2=O Chemical compound CC([C@H](C1)N2c3c1cccc3)Nc(cc(c(OC)c1)O)c1C2=O WHOMMAJWTHZVJY-WRXSAAJRSA-N 0.000 description 1
- KJPKSKLKLWGIOS-UHFFFAOYSA-N COc(c(OCc1cc([N+]([O-])=O)cc(CO)c1)c1)cc(C(C2)=O)c1N=CC1C2c2ccccc2C1 Chemical compound COc(c(OCc1cc([N+]([O-])=O)cc(CO)c1)c1)cc(C(C2)=O)c1N=CC1C2c2ccccc2C1 KJPKSKLKLWGIOS-UHFFFAOYSA-N 0.000 description 1
- DYPFZHNLKQOLFG-LXWOLXCRSA-N C[C@@H](C(N[C@@H](C)C(Nc1cc(CCl)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)=O)=O)NC(CCCCC(OC)=O)=O Chemical compound C[C@@H](C(N[C@@H](C)C(Nc1cc(CCl)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)=O)=O)NC(CCCCC(OC)=O)=O DYPFZHNLKQOLFG-LXWOLXCRSA-N 0.000 description 1
- MYVRXOUKNZBDNS-UWVGGRQHSA-N C[C@@H](C(N[C@@H](C)C(Nc1cc(CO)cc(CO)c1)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(Nc1cc(CO)cc(CO)c1)=O)=O)NC MYVRXOUKNZBDNS-UWVGGRQHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195023P | 2015-07-21 | 2015-07-21 | |
| US201662327973P | 2016-04-26 | 2016-04-26 | |
| PCT/US2016/043414 WO2017015502A1 (en) | 2015-07-21 | 2016-07-21 | Methods of preparing cytotoxic benzodiazepine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3325482T3 true DK3325482T3 (da) | 2020-09-28 |
Family
ID=56557925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16745598.9T DK3325482T3 (da) | 2015-07-21 | 2016-07-21 | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |
| DK16745961.9T DK3325483T3 (da) | 2015-07-21 | 2016-07-21 | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16745961.9T DK3325483T3 (da) | 2015-07-21 | 2016-07-21 | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |
Country Status (23)
| Country | Link |
|---|---|
| US (11) | US9890179B2 (https=) |
| EP (7) | EP3653628B1 (https=) |
| JP (8) | JP6858745B2 (https=) |
| KR (5) | KR20240055894A (https=) |
| CN (5) | CN108290895B (https=) |
| AU (7) | AU2016297087B2 (https=) |
| CA (4) | CA3227588A1 (https=) |
| CY (2) | CY1122553T1 (https=) |
| DK (2) | DK3325482T3 (https=) |
| ES (4) | ES2959741T3 (https=) |
| HK (1) | HK1252322A1 (https=) |
| HR (1) | HRP20201479T1 (https=) |
| HU (1) | HUE051541T2 (https=) |
| IL (10) | IL286788B2 (https=) |
| LT (2) | LT3325483T (https=) |
| PL (2) | PL3325482T3 (https=) |
| PT (2) | PT3325483T (https=) |
| RS (2) | RS60840B1 (https=) |
| RU (3) | RU2018105752A (https=) |
| SG (2) | SG10202106529XA (https=) |
| SI (2) | SI3325482T1 (https=) |
| SM (2) | SMT202000506T1 (https=) |
| WO (3) | WO2017015496A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202106529XA (en) * | 2015-07-21 | 2021-07-29 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| EP3433875B1 (de) | 2016-03-22 | 2022-05-04 | EV Group E. Thallner GmbH | Verfahren zum bonden von substraten |
| KR20240000650A (ko) | 2016-10-19 | 2024-01-02 | 인벤라 인코포레이티드 | 항체 구조물 |
| EP3559039A1 (en) | 2016-12-22 | 2019-10-30 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| EP4148044A1 (en) | 2017-01-25 | 2023-03-15 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| KR20210098470A (ko) * | 2018-11-12 | 2021-08-10 | 이뮤노젠 아이엔씨 | 세포독성 벤조디아제핀 유도체의 제조 방법 |
| TWI849000B (zh) * | 2018-11-12 | 2024-07-21 | 美商伊繆諾金公司 | 製備細胞毒性苯二氮呯衍生物之方法 |
| EP3947395A1 (en) * | 2019-03-29 | 2022-02-09 | ImmunoGen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
| KR20250031149A (ko) | 2022-06-30 | 2025-03-06 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3763183A (en) | 1972-07-10 | 1973-10-02 | Sterling Drug Inc | 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines |
| US3860600A (en) | 1972-07-10 | 1975-01-14 | Sterling Drug Inc | Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines |
| US4678784A (en) | 1984-04-11 | 1987-07-07 | Mcneilab, Inc. | Method for the treatment of LHRH diseases and conditions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| DE69930328T2 (de) | 1998-08-27 | 2006-12-14 | Spirogen Ltd., Ryde | Dimere Pyrrolobenzodiazepine |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| US6548042B2 (en) * | 2000-08-07 | 2003-04-15 | Arstad Erik | Bis-phosphonate compounds |
| UA75093C2 (en) * | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| CN100522955C (zh) | 2002-08-02 | 2009-08-05 | 伊缪诺金公司 | 含有新型强效紫杉烷的细胞毒性剂及其治疗用途 |
| JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
| RU2338747C2 (ru) | 2003-03-31 | 2008-11-20 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| DE60326060D1 (de) | 2003-03-31 | 2009-03-19 | Council Scient Ind Res | Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung |
| RU2314309C2 (ru) | 2003-03-31 | 2008-01-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе |
| ATE413407T1 (de) | 2003-03-31 | 2008-11-15 | Council Scient Ind Res | Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| WO2005063759A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific And Industrial Research | PROCESS FOR PREPARING PYRROLO[2, 1-c] [1, 4] BENZODIAZEPINE HYBRIDS |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| SI2270010T1 (sl) * | 2004-03-01 | 2012-05-31 | Spirogen Ltd | hidroksi H pirolo c benzodiazepin onski derivati kot ključni intermediati za pripravo C substituiranih pirolobenzodiazepinov |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| GB0412492D0 (en) * | 2004-06-04 | 2004-07-07 | Sterix Ltd | Compound |
| PL1879901T3 (pl) | 2005-04-21 | 2010-06-30 | Medimmune Ltd | Pirolobenzodiazepiny |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US8637664B2 (en) | 2005-10-05 | 2014-01-28 | Spirogen Sarl | Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| ATE475660T1 (de) * | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
| SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
| GB2453402B (en) | 2006-02-13 | 2010-12-22 | Council Scient Ind Res | Novel bis-pyrrolo[2,1.-c] [1,4] benzodiazepine-anthraquinone conjugates and a process for the preparation thereof |
| ES2567402T3 (es) | 2006-05-30 | 2016-04-22 | Genentech, Inc. | Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos |
| PL2019104T3 (pl) | 2007-07-19 | 2014-03-31 | Sanofi Sa | Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne |
| WO2009016647A1 (en) | 2007-08-01 | 2009-02-05 | Council Of Scientific & Industrial Research | Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0822260D0 (en) * | 2008-12-05 | 2009-01-14 | Merten Christoph | Assay |
| US8637558B2 (en) * | 2008-12-30 | 2014-01-28 | Industry-Academic Cooperation Foundation, Chosun University | Thiazolidinedione derivative and use thereof |
| CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| EP2486023A4 (en) | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| CN102666480B (zh) * | 2009-12-08 | 2014-04-09 | 国立大学法人岐阜大学 | 芳香族化合物、低聚核苷酸衍生物合成用修饰载体、低聚核苷酸衍生物及低聚核苷酸构建物 |
| US8962279B2 (en) * | 2009-12-30 | 2015-02-24 | Intel Corporation | Solid-phase chelators and electronic biosensors |
| EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| MX391454B (es) * | 2010-04-15 | 2025-03-05 | Seagen Inc | Compuesto de engarce-fármaco para conjugación a una unidad de ligando. |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US8697688B2 (en) | 2010-04-15 | 2014-04-15 | Seattle Genetics Inc. | Pyrrolobenzodiazepines used to treat proliferative diseases |
| JP6049642B2 (ja) | 2011-02-15 | 2016-12-21 | イミュノジェン・インコーポレーテッド | 複合体の調製方法 |
| CN102234253B (zh) * | 2011-06-02 | 2013-07-03 | 重庆莱美药业股份有限公司 | 一种制备非布索坦中间体的方法 |
| HK1211208A1 (zh) | 2012-08-22 | 2016-05-20 | Immunogen, Inc. | 細胞毒性苯並二氮呯衍生物 |
| JP6694811B2 (ja) * | 2013-10-04 | 2020-05-20 | ノバルティス アーゲー | ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ |
| CN104628772A (zh) | 2013-11-07 | 2015-05-20 | 四川恒康发展有限责任公司 | 一种抗肿瘤前药及其激活剂、组合物和应用 |
| CN103664896B (zh) * | 2013-11-25 | 2016-03-02 | 济南精合医药科技有限公司 | 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法 |
| TW201609152A (zh) * | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
| ES2815353T3 (es) | 2014-09-03 | 2021-03-29 | Immunogen Inc | Derivados de benzodiazepina citotóxicos |
| EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| SG10202106529XA (en) * | 2015-07-21 | 2021-07-29 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| PT3380525T (pt) * | 2015-11-25 | 2024-02-05 | Immunogen Inc | Formulações farmacêuticas e métodos que as utilizam |
-
2016
- 2016-07-21 SG SG10202106529XA patent/SG10202106529XA/en unknown
- 2016-07-21 EP EP19200626.0A patent/EP3653628B1/en active Active
- 2016-07-21 PT PT167459619T patent/PT3325483T/pt unknown
- 2016-07-21 IL IL286788A patent/IL286788B2/en unknown
- 2016-07-21 SM SM20200506T patent/SMT202000506T1/it unknown
- 2016-07-21 HK HK18111602.7A patent/HK1252322A1/zh unknown
- 2016-07-21 AU AU2016297087A patent/AU2016297087B2/en not_active Ceased
- 2016-07-21 JP JP2018502785A patent/JP6858745B2/ja not_active Expired - Fee Related
- 2016-07-21 KR KR1020247012816A patent/KR20240055894A/ko not_active Withdrawn
- 2016-07-21 RU RU2018105752A patent/RU2018105752A/ru not_active Application Discontinuation
- 2016-07-21 AU AU2016297607A patent/AU2016297607A1/en not_active Abandoned
- 2016-07-21 EP EP16745598.9A patent/EP3325482B1/en active Active
- 2016-07-21 CN CN201680051138.1A patent/CN108290895B/zh not_active Expired - Fee Related
- 2016-07-21 KR KR1020187005041A patent/KR102660070B1/ko active Active
- 2016-07-21 IL IL305279A patent/IL305279A/en unknown
- 2016-07-21 SI SI201630923T patent/SI3325482T1/sl unknown
- 2016-07-21 CN CN202110366892.7A patent/CN113087763A/zh active Pending
- 2016-07-21 PL PL16745598T patent/PL3325482T3/pl unknown
- 2016-07-21 ES ES20181645T patent/ES2959741T3/es active Active
- 2016-07-21 WO PCT/US2016/043406 patent/WO2017015496A1/en not_active Ceased
- 2016-07-21 CA CA3227588A patent/CA3227588A1/en active Pending
- 2016-07-21 US US15/216,517 patent/US9890179B2/en not_active Expired - Fee Related
- 2016-07-21 KR KR1020187005040A patent/KR20180038460A/ko not_active Withdrawn
- 2016-07-21 SM SM20200004T patent/SMT202000004T1/it unknown
- 2016-07-21 HR HRP20201479TT patent/HRP20201479T1/hr unknown
- 2016-07-21 CA CA2992082A patent/CA2992082A1/en active Pending
- 2016-07-21 RU RU2018105609A patent/RU2746322C2/ru active
- 2016-07-21 ES ES16745961T patent/ES2764548T3/es active Active
- 2016-07-21 RS RS20201132A patent/RS60840B1/sr unknown
- 2016-07-21 LT LTEP16745961.9T patent/LT3325483T/lt unknown
- 2016-07-21 WO PCT/US2016/043414 patent/WO2017015502A1/en not_active Ceased
- 2016-07-21 EP EP23183947.3A patent/EP4286387A3/en not_active Withdrawn
- 2016-07-21 CN CN201680053120.5A patent/CN108055844A/zh active Pending
- 2016-07-21 DK DK16745598.9T patent/DK3325482T3/da active
- 2016-07-21 SI SI201630578T patent/SI3325483T1/sl unknown
- 2016-07-21 LT LTEP16745598.9T patent/LT3325482T/lt unknown
- 2016-07-21 CA CA2991305A patent/CA2991305C/en active Active
- 2016-07-21 IL IL283355A patent/IL283355B/en unknown
- 2016-07-21 CN CN202110219412.4A patent/CN113004288A/zh active Pending
- 2016-07-21 RS RS20191647A patent/RS59806B1/sr unknown
- 2016-07-21 EP EP16748205.8A patent/EP3325485B1/en active Active
- 2016-07-21 WO PCT/US2016/043402 patent/WO2017015495A1/en not_active Ceased
- 2016-07-21 HU HUE16745598A patent/HUE051541T2/hu unknown
- 2016-07-21 ES ES19200626T patent/ES2933376T3/es active Active
- 2016-07-21 PT PT167455989T patent/PT3325482T/pt unknown
- 2016-07-21 JP JP2018502791A patent/JP6787995B2/ja not_active Expired - Fee Related
- 2016-07-21 DK DK16745961.9T patent/DK3325483T3/da active
- 2016-07-21 EP EP16745961.9A patent/EP3325483B1/en active Active
- 2016-07-21 JP JP2018502800A patent/JP2018522018A/ja not_active Withdrawn
- 2016-07-21 CN CN201680053093.1A patent/CN108026103B/zh not_active Expired - Fee Related
- 2016-07-21 RU RU2018105756A patent/RU2727151C2/ru active
- 2016-07-21 IL IL305989A patent/IL305989A/en unknown
- 2016-07-21 IL IL294651A patent/IL294651B2/en unknown
- 2016-07-21 CA CA2991326A patent/CA2991326A1/en not_active Abandoned
- 2016-07-21 KR KR1020187003181A patent/KR102659706B1/ko active Active
- 2016-07-21 KR KR1020247012991A patent/KR20240055903A/ko not_active Withdrawn
- 2016-07-21 EP EP20181645.1A patent/EP3778602B1/en active Active
- 2016-07-21 EP EP22195446.4A patent/EP4163284A1/en not_active Withdrawn
- 2016-07-21 SG SG10202009354SA patent/SG10202009354SA/en unknown
- 2016-07-21 AU AU2016297608A patent/AU2016297608B2/en not_active Ceased
- 2016-07-21 ES ES16745598T patent/ES2820358T3/es active Active
- 2016-07-21 US US15/216,512 patent/US9873708B2/en active Active
- 2016-07-21 PL PL16745961T patent/PL3325483T3/pl unknown
- 2016-07-21 US US15/216,548 patent/US10081640B2/en active Active
-
2017
- 2017-12-11 US US15/837,832 patent/US10370389B2/en active Active
-
2018
- 2018-01-03 US US15/860,864 patent/US10392407B2/en not_active Expired - Fee Related
- 2018-01-11 IL IL256854A patent/IL256854A/en unknown
- 2018-01-11 IL IL256861A patent/IL256861B/en active IP Right Grant
- 2018-01-11 IL IL256860A patent/IL256860B/en active IP Right Grant
- 2018-09-12 US US16/129,008 patent/US10899775B2/en active Active
-
2019
- 2019-06-06 US US16/433,117 patent/US10787463B2/en active Active
- 2019-06-21 US US16/448,261 patent/US20200017526A1/en not_active Abandoned
- 2019-12-30 CY CY20191101364T patent/CY1122553T1/el unknown
-
2020
- 2020-08-10 IL IL276630A patent/IL276630B/en active IP Right Grant
- 2020-08-10 IL IL276631A patent/IL276631B/en unknown
- 2020-08-12 US US16/991,700 patent/US11420982B2/en active Active
- 2020-09-23 CY CY20201100899T patent/CY1123390T1/el unknown
- 2020-10-28 JP JP2020180147A patent/JP6995178B2/ja not_active Expired - Fee Related
- 2020-11-23 US US17/101,942 patent/US20210171547A1/en not_active Abandoned
-
2021
- 2021-03-24 JP JP2021049502A patent/JP7337114B2/ja active Active
- 2021-04-20 AU AU2021202403A patent/AU2021202403B2/en not_active Ceased
- 2021-05-17 AU AU2021203148A patent/AU2021203148B2/en not_active Ceased
- 2021-12-14 JP JP2021202215A patent/JP7334228B2/ja active Active
-
2022
- 2022-12-14 US US18/080,973 patent/US20230257400A1/en not_active Abandoned
-
2023
- 2023-03-03 AU AU2023201339A patent/AU2023201339A1/en not_active Abandoned
- 2023-04-11 AU AU2023202221A patent/AU2023202221A1/en not_active Abandoned
- 2023-08-16 JP JP2023132536A patent/JP2023162264A/ja not_active Withdrawn
- 2023-08-22 JP JP2023134420A patent/JP2023166434A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| IL264143B (en) | Processes for preparing olaparib | |
| DK3189056T3 (da) | Cytotoksiske benzodiazepinderivater | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3325482T3 (da) | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3237045T3 (da) | Indretning til indgivelse af lægemidler | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3204398T3 (da) | Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer | |
| DK3383436T3 (da) | Forbedret fremgangsmåde til fremstilling af indocyaningrønt | |
| HUE050974T2 (hu) | Eljárás pirimidinszulfamid-származékok elõállítására | |
| DK3191406T3 (da) | Fremgangsmåde til fremstilling af aluminiumchloridderivater | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3166611T3 (da) | Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| IL287119B1 (en) | Bryostatin compounds and methods of preparing the same | |
| DK3274143T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| IL287405A (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| DK3120153T3 (da) | Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid | |
| DK3020358T3 (da) | Fremgangsmåde til fremstilling af tandprotese | |
| DK3148993T3 (da) | Fremgangsmåde til fremstilling af thiazolderivater | |
| DK3500572T3 (da) | Cytisinderivater til behandling af afhængighed |